Elias Jabbour, Hagop M Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica T Leonard, David Gómez-Almaguer, Maria R Baer, Carlo Gambacorti-Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S Wang, Bingxia Wang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Tammie Yeh, Jose-Maria Ribera
IMPORTANCE: In newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits BCR::ABL1 and all single-mutation variants, including T315I. OBJECTIVE: To compare frontline ponatinib vs imatinib in adults with newly diagnosed Ph+ ALL. DESIGN, SETTING, AND PARTICIPANTS: Global registrational, phase 3, open-label trial in adults aged 18 years or older with newly diagnosed Ph+ ALL...
May 9, 2024: JAMA